Provided by Tiger Trade Technology Pte. Ltd.

Lantern Pharma Inc.

1.01
-0.0750-6.91%
Post-market: 1.050.0400+3.96%19:30 EDT
Volume:420.70K
Turnover:428.11K
Market Cap:12.89M
PE:-0.62
High:1.16
Open:1.10
Low:0.9700
Close:1.09
52wk High:4.70
52wk Low:0.9700
Shares:12.76M
Float Shares:9.85M
Volume Ratio:1.13
T/O Rate:4.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6362
EPS(LYR):-1.5709
ROE:-400.92%
ROA:-74.29%
PB:-4.01
PE(LYR):-0.64

Loading ...

Lantern Pharma Raises Capital Through Recent Securities Offerings

TIPRANKS
·
6 hours ago

Lantern Pharma Issues Unregistered Warrants in Private Placement for up to 3,669,725 Shares

Reuters
·
6 hours ago

Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering

THOMSON REUTERS
·
6 hours ago

Lantern Pharma Prices Private Placement Warrants to Buy 3,669,725 Shares at $1.09 Each

Reuters
·
Sep 29

Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering

THOMSON REUTERS
·
Sep 29

Lantern Pharma - Enters Agreement for Sale of 3,669,725 Shares at $1.09 Per Share

THOMSON REUTERS
·
Sep 29

Lantern Pharma to Present Open-Medicine AI Drug Development Platform Roadmap in Live Webinar

Reuters
·
Sep 23

Lantern Pharma secures USPTO notice of allowance for LP-284 patent

TIPRANKS
·
Sep 22

Lantern Pharma Wins USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent Application

Reuters
·
Sep 22

Lantern Pharma Hosts Investor Webinar on Open-Medicine AI Platform Business Model and Roadmap

Reuters
·
Sep 17

Lantern Pharma Earnings Call: AI Spinout, Trial Momentum

TIPRANKS
·
Aug 25

Here's Why We're A Bit Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Simply Wall St.
·
Aug 21

Lantern Pharma Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Lantern Pharma Forms Open Medicine AI Subsidiary Business

TIPRANKS
·
Aug 14

Lantern Pharma Q2 EPS $(0.57) Misses $(0.38) Estimate

Benzinga Earnings
·
Aug 14

Lantern Pharma Q2 EPS USD -0.57

THOMSON REUTERS
·
Aug 14

Lantern Pharma Q2 FY26 Operating Loss Narrows 25% to $3.5 Million; Net Loss Widens to $7.1 Million

Reuters
·
Aug 14

Press Release: Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 14

Lantern Pharma Inc Expected to Post a Loss of 38 Cents a Share - Earnings Preview

Reuters
·
Aug 12

Lantern Pharma Inc Expected to Post a Loss of 38 Cents a Share - Earnings Preview

Reuters
·
Aug 07